The Board of Directors of Immunovia AB decided to appoint Jeff Borcherding, until now President of Immunovia's US operation, as global CEO. Jeff Borcherding replaces Philipp Matthieu. Jeff Borcherding has led Immunovia's US business since April 2022.

Prior to joining Immunovia, he held several positions in the American diagnostics industry, including most recently Chief Marketing Officer at Myriad Genetics. He will continue to lead Immunovia's US business while also taking on the role as global CEO. With this change, the company is simplifying and streamlining its management structure and further emphasizing its focus on commercializing IMMray PanCan-d, the first blood-based test dedicated to early detection of pancreatic cancer, in the United States.

Philipp Mathieu will remain at the Board of Directors' disposal during his notice period, which runs for six months from today's date.